Navigation Links
Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study

- Results Presented at the 12th Congress of European Hematology Association (EHA) -

VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that data presented at the 12th Congress of EHA in Vienna, Austria, showed positive responses in patients with non-Hodgkin's lymphoma (NHL) treated with a new radioimmunotherapy (RAIT) using epratuzumab to deliver toxic radiation directly to lymphoma cells in small fractions. Franck Morschhauser, MD, Centre Hospitalier Regional Universitaire de Lille, Lille, France, is the lead investigator of this open-label, multicenter Phase I/II dose-escalation study and the presenter at the meeting.

Current RAIT treatments for NHL such as tositumomab and ibritumomab tiuxetan are radiolabeled murine antibodies targeting the CD20 antigen on the surface of mature B-cells and B-cell tumors as expressed by NHL cells. Immunomedics' epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen. Moreover, because epratuzumab is humanized, it is argued that the new RAIT can be administered to patients repeatedly in smaller doses. Researchers found that splitting the dose over two or three fractions made it tolerable to patients while delivering higher radioactivity to tumor cells.

At the time of reporting, 54 patients were evaluated with an overall objective response rate of 59% and a complete response rate of 43%. Moreover, responses appear durable with 6 complete responders who remained disease free for more than 1 year, including 4 continuing for more than 2 years.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
9. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Human Insulin Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore more ...
(Date:7/28/2015)... LINCOLNSHIRE, Ill. , July 28, 2015 ... acumen on par with their levels of clinical excellence. ... (AACC) Annual Meeting & Clinical Lab Expo, Sysmex is ... deliver a comprehensive and intuitive ecosystem that will help ... four key areas, Sysmex aims to add even more ...
(Date:7/28/2015)... July 28, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq: ... report its second quarter 2015 financial results after market ... management will follow the announcement with a live ... (1:30pm Pacific Time) to discuss the financial results. ... call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5Sysmex Moves Beyond a Better Box 2Sysmex Moves Beyond a Better Box 3Sysmex Moves Beyond a Better Box 4Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist ... a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, ... of her esteemed colleagues and peers in the metro area as one of the ...
(Date:7/28/2015)... ... July 28, 2015 , ... The PULs ... Sudden Death, or Angina), many of whom are missed by conventional evaluation ... with active yet undetected sub-clinical disease, who are at risk of experiencing a ...
(Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys today announced that ... of the EY Entrepreneur of the Year award. The award recognizes the important ... and the innovative work they have done in incorporating new technology, processes, and ...
(Date:7/28/2015)... ... 28, 2015 , ... Please join us for the 5th Annual Step for Hope 5K ... Gary Avenue and Lies Road in Carol Stream. All are welcome. , Now in ... education and help to support individuals and families affected by a brain aneurysm. , ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Intellitec Solutions ... Accounting Today’s annual ranking of Value Added Resellers of ERP Software is a look ... are presented with. This honor represents the second such award in 2015 for Intellitec ...
Breaking Medicine News(10 mins):Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2
... "As a physician,you hear all sorts of excuses for ... Medical Director of First Coast Family Medicine and clinical,spokesperson ... common that Dr. Hashey reports is the excuse that ... couldn,t be farther from the truth.,The flu shot is ...
... October 17 - For the Nine Months (to 31 ... Months Almost Six-Fold Growth in EBIT to EUR34.8m (EUR6.2m) - ... Substantial Debt Reduction and Fall in Interest Charges Since the IPO ... Our,Full-Year Forecast for 2007." In the first nine months of ...
... hold a press availability tomorrow, Wednesday, October 17, at 10:30,a.m. ... 2-year-old,from Tampa, Fla., who was born with a serious heart ... is on Capitol Hill urging Members of,Congress to vote to ... 10 million children., WHO: Speaker Nancy ...
... the U.S. Food and Drug,Administration,s (FDA,s) Cardiovascular ... majority of members voted to recommend the ... FOSRENOL(R),(lanthanum carbonate), to treat hyperphosphatemia (elevated levels ... disease (CKD) Stage 4 patients.,Currently, FOSRENOL is ...
... the race to the 2008 elections,heats up, nearly every ... coverage. "But when it comes to the already ... of industry players is a more,overarching consideration than the ... Standard & Poor,s Ratings Services,in a report published Oct. ...
... yogurt(TM) in an easy-to-swallow caplet., VANCOUVER, Wash., ... of AccuFlora Pro-Biotic Acidophilus, a combination of,five types ... a healthy immune system with the good stuff ... MayoClinic.com, there is growing public and scientific,interest in ...
Cached Medicine News:Health News:Flu Myths Abound in Flu Season 2Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 2Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 3Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 2Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 4Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 6Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 7Health News:S&P: Leverage Tops Politics as Primary Credit Concern for U.S. Health Care Companies, Says S&P 2Health News:Northwest Natural Products Introduces AccuFlora(R) 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: